Immunome (IMNM) CSO pre-planned 9,438-share sale under Rule 10b5-1

Rhea-AI Filing Summary

Immunome Inc. Chief Scientific Officer Jack Higgins sold 9,438 shares of common stock at $21.64 per share on April 2, 2026 in an open-market transaction. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 19, 2025, indicating it was scheduled in advance. Following the sale, Higgins directly holds 22,000 shares of Immunome common stock. He is also listed as custodian for three separate 1,000-share accounts for his children under the Uniform Transfer to Minors Act, but he disclaims beneficial ownership of those custodial shares, which are subject to a lockup agreement dated December 15, 2025.

Insights

Equity compensation and insider-trading analyst

Pre-planned sale of 9,438 Immunome shares by CSO looks routine.

The Chief Scientific Officer of Immunome Inc. executed an open-market sale of 9,438 common shares at $21.64 each. This transaction was carried out under a Rule 10b5-1 trading plan adopted on December 19, 2025, suggesting it was scheduled in advance rather than opportunistic.

After the sale, he still directly owns 22,000 shares, indicating he retains a meaningful equity stake. Additional 1,000-share custodial accounts for three children are disclosed, but he disclaims beneficial ownership and those shares are subject to a lockup agreement from December 15, 2025. Overall, this filing reflects a routine, pre-planned insider sale rather than a major shift in insider exposure.

Insider Trade Summary 10b5-1

Net Seller: 9,438 shares ($204,238)

Net Sell 4 txns

Insider Higgins Jack

Role Chief Scientific Officer

Sold 9,438 shs ($204K)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,438	$21.64	$204K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 22,000 shares (Direct); Common Stock — 1,000 shares (Indirect, As Custodian for Child 1)

Footnotes (1)

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. The Reporting Person serves as a custodian of a custodial account for his child pursuant to the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose. The shares are subject to a lockup agreement entered into by the Reporting Person on December 15, 2025.

Key Figures

Shares sold: 9,438 shares Sale price: $21.64 per share Direct holdings after sale: 22,000 shares +3 more

6 metrics

Shares sold 9,438 shares Open-market sale on April 2, 2026

Sale price $21.64 per share Price for 9,438 Immunome common shares sold

Direct holdings after sale 22,000 shares Common stock directly held by Jack Higgins post-transaction

Child 1 custodial account 1,000 shares Indirect holding as custodian under UTMA

Child 2 custodial account 1,000 shares Indirect holding as custodian under UTMA

Child 3 custodial account 1,000 shares Indirect holding as custodian under UTMA

Key Terms

Rule 10b5-1 trading plan, Uniform Transfer to Minors Act, beneficial ownership, Section 16, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Uniform Transfer to Minors Act regulatory

"serves as a custodian of a custodial account for his child pursuant to the Uniform Transfer to Minors Act"

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership of these shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Section 16 regulatory

"shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

lockup agreement financial

"The shares are subject to a lockup agreement entered into by the Reporting Person on December 15, 2025"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Higgins Jack

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/02/2026		S(1)		9,438	D	$21.64	22,000	D
Common Stock								1,000(2)	I	As Custodian for Child 1
Common Stock								1,000(2)	I	As Custodian for Child 2
Common Stock								1,000(2)	I	As Custodian for Child 3

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.

2. The Reporting Person serves as a custodian of a custodial account for his child pursuant to the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose. The shares are subject to a lockup agreement entered into by the Reporting Person on December 15, 2025.

	/s/ Sandra Stoneman, Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Immunome (IMNM) Chief Scientific Officer Jack Higgins do in this Form 4?

Jack Higgins reported selling 9,438 shares of Immunome common stock at $21.64 per share. The transaction was an open-market sale executed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, indicating it was scheduled in advance.

How many Immunome (IMNM) shares does Jack Higgins hold after the reported sale?

After the sale, Jack Higgins directly holds 22,000 shares of Immunome common stock. The filing also lists three separate 1,000-share custodial accounts for his children, but he disclaims beneficial ownership of those indirect holdings under the Uniform Transfer to Minors Act.

Was the Immunome (IMNM) insider sale by Jack Higgins part of a Rule 10b5-1 plan?

Yes. The filing states the 9,438-share sale was effected under a Rule 10b5-1 trading plan adopted on December 19, 2025. Such plans pre-schedule trades, which can make the timing less informative about the insider’s current view of the stock.

What does it mean that Jack Higgins disclaims beneficial ownership of certain Immunome (IMNM) shares?

Higgins is custodian for three 1,000-share accounts for his children under the Uniform Transfer to Minors Act but disclaims beneficial ownership. This means he reports these indirect holdings for transparency but does not treat them as his own economic interest for Section 16 purposes.

Are any of the Immunome (IMNM) shares related to Jack Higgins subject to a lockup agreement?

Yes. The filing notes that the custodial shares for his children are subject to a lockup agreement entered into on December 15, 2025. A lockup agreement restricts sales of those shares for a defined period, limiting immediate liquidity from those holdings.